Trial Outcomes & Findings for In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (NCT NCT05023304)

NCT ID: NCT05023304

Last Updated: 2025-08-17

Results Overview

Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

30 participants

Primary outcome timeframe

Post-op Day 1

Results posted on

2025-08-17

Participant Flow

Contralateral eye study with randomization of one eye receiving a dexamethasone ophthalmic insert 0.4mg and the other eye receiving topical prednisolone acetate 1% four times daily for one week, three times daily for one week, two times daily for one eye, and then one time daily for one week.

60 eyes of 30 patients enrolled

Unit of analysis: Eyes

Participant milestones

Participant milestones
Measure
Group A Dextenza Ophthalmic Insert 0.4mg
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone Acetate 1%
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Overall Study
STARTED
30 30
30 30
Overall Study
COMPLETED
30 30
30 30
Overall Study
NOT COMPLETED
0 0
0 0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group A Dextenza
n=30 Eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 Eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Total
n=60 Eyes
Total of all reporting groups
Age, Continuous
67 years
STANDARD_DEVIATION 0.389 • n=30 Participants
67 years
STANDARD_DEVIATION 0.389 • n=30 Participants
67 years
STANDARD_DEVIATION 0.389 • n=60 Participants
Sex: Female, Male
Female
17 Participants
n=30 Participants
17 Participants
n=30 Participants
34 Participants
n=60 Participants
Sex: Female, Male
Male
13 Participants
n=30 Participants
13 Participants
n=30 Participants
26 Participants
n=60 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Pain Score 0-10
2 units on a scale
n=30 Eyes
2 units on a scale
n=30 Eyes
2 units on a scale
n=60 Eyes

PRIMARY outcome

Timeframe: Post-op Day 1

Population: Contralateral eye study of 30 patients. A total of 60 eyes analyzed with 30 eyes randomized to each group.

Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Mean Anterior Chamber Cell/Flare Score
1.06 Units on a scale
Interval 0.0 to 4.0
1.15 Units on a scale
Interval 0.0 to 4.0

PRIMARY outcome

Timeframe: Post-op Day 7

Population: Contralateral eye study of 30 patients. A total of 60 eyes analyzed with 30 eyes randomized to each group.

Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50. The higher the HPF, the more inflammation that can negatively impact a patient's outcome.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Mean Anterior Chamber Cell/Flare Score
0.25 score on a scale
Interval 0.0 to 4.0
0.22 score on a scale
Interval 0.0 to 4.0

PRIMARY outcome

Timeframe: post-op Week 4.

Population: Contralateral eye study of 30 patients. A total of 60 eyes analyzed with 30 eyes randomized to each group.

Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50. The higher the HPF, the more inflammation that can negatively impact a patient's outcome.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Number of Eyes With No Cell or Flare Measured
30 eyes
28 eyes

PRIMARY outcome

Timeframe: Post-op Day 1

Mean pain score measured by Visual Analog Score numerical grading scale 0(minimum)-10(maximum) 0= absence of pain 10 = highest possible pain A higher number indicates a higher pain value which may impact a subject's outcomes.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Mean Pain Score
Pain score 0
23 Participants
23 Participants
Mean Pain Score
Pain score 1
2 Participants
2 Participants
Mean Pain Score
Pain score 2
2 Participants
3 Participants
Mean Pain Score
Pain score 3
2 Participants
2 Participants
Mean Pain Score
Pain score 4
1 Participants
0 Participants

PRIMARY outcome

Timeframe: Post-op Week 4

Population: 30 patients in each cohort or 60 eyes

As measured by adapted COMTOL (Comparison of Ophthalmic Medications for Tolerability) Questionnaire. The COMTOL questionnaire is designed to assess the tolerability of topical ophthalmic medications. It consists of several elements that help evaluate the frequency, severity, and impact of common side effects: Section 1: Ocular Side Effects; Section 2: Local Side Effects; Section 3: Visual Function; Section 4: Impact on Quality of Life. Likert scale is used to measure each question. 1=Never, 2=Rarely, 3=Sometimes, 4 = Often, 5= Always. A higher score suggests that the medication is less well-tolerated and may be negatively impacting the patient's daily activities and overall well-being.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Patient Tolerability (Defined as Patient Preference)
No Preference
1 Participants
Patient Tolerability (Defined as Patient Preference)
Preferred Dexamethasone Inserts
29 Participants
Patient Tolerability (Defined as Patient Preference)
Preferred Preferred topical prednisolone acetate
0 Participants

SECONDARY outcome

Timeframe: postop Day 1

Intraocular pressure as measured by Goldmann Applanation Tonometer; Total number of Participants with Increased IOP \>10mmHg above baseline. Normal intraocular pressure (IOP) is generally considered to be between 10 and 21 millimeters of mercury (mmHg). However, it's important to note that this is just a general range, and individual values can vary. A higher IOP may negatively impact a subject's outcome.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Number of Participants With Increased Intraocular Pressure (IOP) >10mmHg Above Baseline
1 Participants
0 Participants

SECONDARY outcome

Timeframe: Postop Day 7

Intraocular pressure as measured by Goldmann Applanation Tonometer; Total number of Participants with Increased IOP \>10mmHg above baseline. Normal intraocular pressure (IOP) is generally considered to be between 10 and 21 millimeters of mercury (mmHg). However, it's important to note that this is just a general range, and individual values can vary. A higher IOP may negatively impact a subject's outcome.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Number of Participants With Increased Intraocular Pressure (IOP) >10mmHg Above Baseline
0 Participants
0 Participants

SECONDARY outcome

Timeframe: postop Week 4

Intraocular Pressure as measured by Goldmann Applanation Tonometer, Total number of Participants with increased IOP \> 10mmHg above baseline. Normal intraocular pressure (IOP) is generally considered to be between 10 and 21 millimeters of mercury (mmHg). However, it's important to note that this is just a general range, and individual values can vary. A higher IOP may negatively impact a subject's outcome.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Number of Participants With Increased Intraocular Pressure (IOP) >10mmHg Above Baseline
0 Participants
0 Participants

SECONDARY outcome

Timeframe: post-op Week 4

Cystoid Macular Edema (CME) as measured by optical coherence tomography (OCT); Total number of study participants with post-operative CME.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Number of Participants With Post-operative Cystoid Macular Edema (CME)
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Day 0

Population: Not applicable to Group B

Physician Ease of Use Survey following dexamethasone intracanalicular placement on Surgical Visit on Scale of 0-10 with 10 being most complex (0= minimum value or not complex and 10= maximum complexity). A higher number indicates a worse outcome.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Physician Ease of Use
3.9 Score on a scale
Interval 0.0 to 10.0

SECONDARY outcome

Timeframe: Post-op Day 7

Population: 1 patient did not complete questionnaire. Patients were not asked to differentiate between eyes when answering the eye drop burden questionnaire

Eye Drop Burden Questionnaire numerical grading scale 8 questions on scale of 1-5 totaling a maximum score of 40. Likert scale used: 1 Very easy, 2. Easy 3. Neither easy nor difficult 4. Difficult 5. Very difficult Low Burden=8-18 Moderate Burden=19-29 High Burden= 30-40 A higher number score indicates a negative outcome for a subject.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=29 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Eye Drop Burden Reported by Participants
Low burden (maximum score between 8-18)
27 Participants
Eye Drop Burden Reported by Participants
Moderate burden (maximum score between 19-29)
2 Participants
Eye Drop Burden Reported by Participants
High burden (maximum score between 30-40)
0 Participants

SECONDARY outcome

Timeframe: post-op Week 4. Patients were not asked to differentiate between eyes when answering the eye drop burden questionnaire

Eye Drop Burden Questionnaire numerical grading scale 8 questions on scale of 1-5 totaling a maximum score of 40. Likert scale used: 1 Very easy, 2. Easy 3. Neither easy nor difficult 4. Difficult 5. Very difficult Low Burden=8-18 Moderate Burden=19-29 High Burden= 30-40 A higher score is considered a worse outcome for a subject.

Outcome measures

Outcome measures
Measure
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery. Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery. Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
Eye Drop Burden Reported by Participants
Low burden (maximum score between 8-18)
28 Participants
Eye Drop Burden Reported by Participants
Moderate burden (maximum score between 19-29)
2 Participants
Eye Drop Burden Reported by Participants
High burden (maximum score between 30-40)
0 Participants

Adverse Events

Group A Dextenza

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group B Topical Prednisolone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Director of Clinical Trials

Vance Thompson Vision

Phone: 1-605-371-7075

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place